PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease ReportsSquamous cell carcinoma
MeSH D002294 - squamous cell carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D018307:Squamous cell neoplasms
2 Companies
2 Drugs
$
Success rate
D002277:Carcinoma
18 Companies
3 Drugs
$
Success rate
D002294: 
Squamous cell carcinoma
18 Companies
8 Drugs
$
Success rate
D000077277:Esophageal squamous cell carcinoma
2 Companies
1 Drug
$
Success rate
D001913:Bowen's disease
0 Companies
0 Drugs
Success rate
D000077195:Squamous cell carcinoma of head and neck
2 Companies
2 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaBleomycin Bleomycin  1996-06-01   
CiplaBleomycin Bleomycin  2019-03-11   
Boehringer IngelheimAfatinib Gilotrif 2026-01-13 2013-07-12   
Afatinib Giotrif  2013-09-25   
Merck & CoCetuximab Erbitux  2004-06-29   
Pembrolizumab Keytruda  2014-09-04 $28,253 M Q4/23-Q3/24 
Eli LillyCetuximab Erbitux  2004-02-12 $602.6 M Q4/23-Q3/24 
Barr PharmaceuticalsHydroxyurea Hydroxyurea  1998-07-30   
HospiraBleomycin Bleomycin  2000-03-10   
Bristol Myers SquibbBleomycin Blenoxane  1982-01-01   
Nivolumab Nivolumab BMS  2015-07-20   
Nivolumab Opdivo  2014-12-22 $9,212 M Q4/23-Q3/24 
Nivolumab, Relatlimab Opdualag  2022-03-18 $864 M Q4/23-Q3/24 
EndoHydroxyurea Hydroxyurea  1999-02-24   
Hikma PharmaceuticalsBleomycin Bleomycin  2001-10-17   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
63%
47/75
Phase 2
20%
21/106
Phase 3
43%
15/35
Approved: 11Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Bleomycin,
Transplatin,
Antithrombin iii,
Bolus
Cipla
Bleomycin
Boehringer Ingelheim
Afatinib,
Docusate,
Transplatin,
Antithrombin iii,
Lampalizumab,
Bevifimod,
Telbermin,
Edetic acid,
Nerofe,
Mk3475,
Mmc,
Pcd,
Docetaxol,
Mephedrone
Merck & Co
Pembrolizumab,
Cetuximab,
Transplatin,
Albumin,
Antithrombin iii,
Feladilimab,
Epacadostat,
Aglatimagene besadenovec,
Ademetionine,
Doconexent,
Sodium chloride,
Sodium lactate,
Bevifimod,
Favezelimab,
LADIRATUZUMAB VEDOTIN,
Nepidermin,
PEPINEMAB,
Vilobelimab,
Microcrystalline cellulose,
Mk-4280,
Saha,
Nerofe,
Gardasil,
Mk3475,
Q2w,
ISA101B,
Hiltonol,
Sbrt,
Tmz,
Arm1,
Bca101,
Beam,
Flt3l,
Pcd,
Arm2,
Docetaxol,
Gb1275,
Taxane,
Iclc
Eli Lilly
Cetuximab,
Transplatin,
Aglatimagene besadenovec,
Edrecolomab,
Calcium dobesilate,
Doconexent,
Sodium chloride,
Bevifimod,
CIXUTUMUMAB,
LITRONESIB,
PREXASERTIB,
Cdp1,
Viaject,
Mk3475,
Q2w,
Arm1,
Arm2,
Fluoropyrimidine,
Evidence
Bristol Myers Squibb
Nivolumab,
Bleomycin,
Relatlimab,
Transplatin,
Albumin,
Antithrombin iii,
Nogapendekin alfa,
Linrodostat,
Epacadostat,
Inbakicept,
Ademetionine,
Doconexent,
Fludeoxyglucose f-18,
Sodium chloride,
Bevifimod,
LIRILUMAB,
Nepidermin,
Vilobelimab,
N803,
Tpf,
Mk3475,
Q2w,
Arm1,
Pcd,
Arm2,
Bolus,
Docetaxol
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use